自闭症临床试验生物标志物联盟:候选脑电生物标志物组合的初步评估
本研究在6–11岁自闭症谱系障碍(ASD)儿童(N=280)和典型发育儿童(N=119)中,多站点自然状态下评估了一套脑电(EEG)检测组合的心理测量学特性,包括采集率、构念效度和6周稳定性。面部任务(P1、N170)在采集率、构念表现、组间区分和表型相关上均显示前景,静息态和视觉诱发电位(VEP)结果不一,生物运动知觉检测未显示构念表现。
要点
- 面部任务P1和N170潜伏期在ASD组6周稳定性中等(组内相关系数≥0.66)。
- 面部任务P1和N170是组间区分和表型相关的主要观察指标。
- 静息态α功率和VEP的N1、P1波幅在ASD组6周稳定性中等(组内相关系数≥0.66)。
核心结论
- 在ASD临床试验候选EEG生物标志物的大规模严格评估中,面部神经反应成为有前景、值得继续评估的生物标志物。
- 静息态活动和VEP结果不一,生物运动知觉检测未显示构念表现。
研究设计与样本
- 大型、多站点、自然状态研究,纳入6–11岁ASD诊断儿童(N=280)和典型发育儿童(N=119)。
- 评估的EEG组合包括静息态活动、面部知觉(面部任务)、生物运动知觉和视觉诱发电位(VEP)检测。
- 生物标志物心理测量学从采集率、构念表现和6周稳定性三方面评估。
主要发现
- 三项检测(静息态、面部任务和VEP)在采集率和构念表现方面显示前景。
- ASD组6周稳定性中等(组内相关系数≥0.66)见于面部任务P1和N170潜伏期、VEP的N1和P1波幅及静息α功率。
- 组间区分和表型相关主要见于面部任务P1和N170。
- 生物运动知觉检测未显示构念表现。
关键数值与推荐
- ASD组6周稳定性:面部任务P1和N170潜伏期、VEP的N1和P1波幅及静息α功率的组内相关系数≥0.66。
- 组间区分和表型相关主要见于面部任务P1和N170。
临床怎么用
- 面部任务P1和N170可作为ASD临床试验中继续评估的有前景EEG生物标志物。
- 静息态活动和VEP在ASD临床试验中的生物标志物适用性结果不一。
- 生物运动知觉检测未显示构念表现,不支持其作为候选生物标志物继续评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Numerous candidate EEG biomarkers have been put forward for use in clinical research on autism spectrum disorder (ASD), but biomarker development has been hindered by limited attention to the psychometric properties of derived variables, inconsistent results across small studies, and variable methodology. The authors evaluated the basic psychometric properties of a battery of EEG assays for their potential suitability as biomarkers in clinical trials. METHODS: This was a large, multisite, naturalistic study in 6- to 11-year-old children who either had an ASD diagnosis (N=280) or were typically developing (N=119). The authors evaluated an EEG battery composed of well-studied assays of resting-state activity, face perception (faces task), biological motion perception, and visual evoked potentials (VEPs). Biomarker psychometrics were evaluated in terms of acquisition rates, construct performance, and 6-week stability. Preliminary evaluation of use was explored through group discrimination and phenotypic correlations. RESULTS: Three assays (resting state, faces task, and VEP) show promise in terms of acquisition rates and construct performance. Six-week stability values in the ASD group were moderate (intraclass correlations ≥0.66) for the faces task latency of the P1 and N170, the VEP amplitude of N1 and P1, and resting alpha power. Group discrimination and phenotype correlations were primarily observed for the faces task P1 and N170. CONCLUSIONS: In the context of a large-scale, rigorous evaluation of candidate EEG biomarkers for use in ASD clinical trials, neural response to faces emerged as a promising biomarker for continued evaluation. Resting-state activity and VEP yielded mixed results. The study's biological motion perception assay failed to display construct performance. The results provide information about EEG biomarker performance that is relevant for the next stage of biomarker development efforts focused on context of use.
引用
- Webb SJ, Naples AJ, Levin AR, et al. The Autism Biomarkers Consortium for Clinical Trials: Initial Evaluation of a Battery of Candidate EEG Biomarkers. Am J Psychiatry. 2022. PMID: 36000217. doi:10.1176/appi.ajp.21050485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。